Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus CLARITIN D 24 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus CLARITIN D 24 HOUR.
CLARITIN HIVES RELIEF vs CLARITIN-D 24 HOUR
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Selective inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in allergic reactions.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism; pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction in the nasal mucosa.
FDA: Relief of symptoms associated with seasonal allergic rhinitis (sneezing, rhinorrhea, nasal pruritus, ocular pruritus) and chronic idiopathic urticaria.FDA: Relief of hives (urticaria) and itching.
Relief of symptoms of seasonal allergic rhinitis (e.g., sneezing, rhinorrhea, nasal congestion, pruritus)Relief of nasal congestion associated with the common cold
10 mg orally once daily
1 tablet (10 mg loratadine/240 mg pseudoephedrine) orally once daily
None Documented
None Documented
8.4 hours (range 3-20 hours) for loratadine; 28 hours (range 8.8-92 hours) for active metabolite desloratadine, allowing once-daily dosing.
Loratadine: 8-11 hours (mean 10.6 ± 4.6 h); desloratadine: 17-24 hours (mean 19.4 ± 7.5 h). Terminal half-life is prolonged in chronic hepatic impairment (mean 37 h for loratadine, 47 h for desloratadine).
Primarily hepatic via CYP3A4 and CYP2D6; forms active metabolite desloratadine.
Loratadine: extensively metabolized by CYP3A4 and CYP2D6 to active metabolite desloratadine; pseudoephedrine: partially metabolized in liver by N-demethylation.
Renal: ~40% as metabolites, <1% unchanged; Fecal: ~40%; Biliary: minor contribution.
Renal (40%) as unchanged drug and metabolites; biliary/fecal (minor). Approximately 27% of loratadine and 40% of desloratadine are excreted in urine over 10 days.
Loratadine: 97-99% to albumin and alpha-1-acid glycoprotein; desloratadine: 73-76%.
Loratadine: 97-99% bound to plasma proteins (mainly albumin and α1-acid glycoprotein); desloratadine: 73-76% bound.
Loratadine: 120 L/kg, indicating extensive tissue distribution; desloratadine: 40 L/kg.
Loratadine: 119 L/kg (apparent Vd/F ~1000 L). High Vd indicates extensive tissue distribution. Desloratadine: 148 L/kg (apparent Vd/F ~2500 L).
Oral: ~100% (loratadine is rapidly and well absorbed; first-pass metabolism to desloratadine reduces parent drug concentration but active metabolite contributes to effect).
Oral: Loratadine absolute bioavailability is ~40% due to first-pass metabolism; food increases AUC by 40% and delays Tmax. Desloratadine absolute bioavailability is ~50%.
GFR 30-89 mL/min: no adjustment; GFR <30 mL/min: 5 mg orally once daily
GFR 30-89 mL/min: no adjustment; GFR <30 mL/min or ESRD: contraindicated due to pseudoephedrine component
Child-Pugh A: no adjustment; Child-Pugh B or C: 5 mg orally once daily
Child-Pugh class A: no adjustment; Child-Pugh class B or C: contraindicated due to insufficient data
6-11 years: 5 mg orally once daily; 12 years and older: 10 mg orally once daily
Not recommended for children under 12 years; age 12-17 years: 1 tablet orally once daily
No specific adjustment; use caution due to age-related renal impairment may require 5 mg once daily
Caution in patients >60 years due to increased sensitivity to pseudoephedrine (nervousness, dizziness, sleep disturbances) and higher risk of adverse effects; consider alternative therapy
None.
None.
Caution in patients with hepatic or renal impairment; avoid use with alcohol or CNS depressants; may cause drowsiness or dizziness; use with caution in elderly patients.
["Cardiovascular effects: caution in hypertension, arrhythmias, ischemic heart disease","Central nervous system stimulation: may cause insomnia, dizziness, tremor","Urinary retention: caution in patients with prostatic hypertrophy","Glaucoma: may increase intraocular pressure","Use with MAOIs: hypertensive crisis risk","Diabetes: may increase blood glucose"]
Hypersensitivity to loratadine or any component; severe hepatic impairment; pediatric patients <6 years of age (for this product).
["Hypersensitivity to loratadine, pseudoephedrine, or any component","Severe hypertension","Severe coronary artery disease","Concurrent use or within 14 days of MAOIs","Narrow-angle glaucoma","Urinary retention","Lactation (due to pseudoephedrine)"]
Data Pending Review
Data Pending Review
No significant food interactions; grapefruit juice does not affect loratadine metabolism. Avoid alcohol as it may potentiate CNS depression.
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) due to potential hypertensive crisis with pseudoephedrine. Grapefruit juice may increase pseudoephedrine absorption; limit intake. Avoid alcohol, which can exacerbate CNS sedation from loratadine.
Loratadine is categorized as FDA Pregnancy Category B. Animal studies have not demonstrated fetal harm, but adequate, well-controlled studies in pregnant women are lacking. No known teratogenic risk in any trimester; however, first-trimester exposure should be with caution.
FDA Pregnancy Category B. Animal studies show no fetal risk; no adequate human studies in first trimester. Pseudoephedrine may cause uterine vasoconstriction; avoid in preeclampsia or reduced placental perfusion. No known teratogenicity from loratadine or pseudoephedrine in human pregnancy.
Loratadine is excreted into breast milk; M/P ratio is approximately 1.17 for parent drug and 0.85 for active metabolite. Concentrations are low, and adverse effects in nursing infants are unlikely. Considered compatible with breastfeeding, but monitor infant for sedation or irritability.
Loratadine: M/P ratio ~1.2; excreted in breast milk in low amounts (0.029% of maternal dose). Pseudoephedrine: M/P ratio ~3.5; excreted in milk (4-6% of maternal dose), may reduce milk production and cause irritability in infants. Use caution, especially with high doses or prolonged use.
No specific dose adjustment is required during pregnancy. Pharmacokinetic changes (increased plasma volume, altered hepatic metabolism) may reduce serum concentrations, but clinical efficacy is maintained with standard doses (10 mg once daily).
No dose adjustment typically required; pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) are not significant enough to require dose modification. Use lowest effective dose, avoid in severe hypertension or coronary artery disease.
Category C
Category C
Loratadine is a second-generation antihistamine with minimal anticholinergic effects; onset of action within 1-3 hours, duration 24 hours; not effective for acute urticaria in some patients; may require dose adjustment in hepatic impairment (Child-Pugh class B or C).
CLARITIN-D 24 HOUR combines loratadine (antihistamine) and pseudoephedrine (decongestant). Avoid in patients with severe hypertension, coronary artery disease, or MAOI use within 14 days. Monitor for insomnia, tachycardia, and urinary retention, especially in elderly males with BPH. Contraindicated in narrow-angle glaucoma.
Take once daily with or without food.Do not exceed recommended dose; may cause drowsiness in some individuals.Avoid alcohol as it may increase drowsiness.If symptoms persist after 3 days, consult a healthcare provider.Not recommended for children under 6 years without medical advice.
Do not crush or chew the tablet; swallow whole with a full glass of water.Avoid taking within 4-6 hours of bedtime to prevent insomnia.Do not use with other decongestants or cold remedies containing pseudoephedrine.Discontinue and consult healthcare provider if you experience chest pain, rapid heart rate, dizziness, or difficulty urinating.